Nevertheless, modulation of Cdc42 activity and its regulatory pathways might serve as a therapeutic target to prevent a vicious cycle in which kidney damage and impaired insulin secretion interact with each other and ultimately lead to an aggravated outcome. This evidence concerns the gene CDC42 and Nephropathy.